The second interim analysis of the TROPiCS-02 trial—which studied the efficacy of the TROP2–directed antibody-drug conjugate sacituzumab govitecan-hziy in patients with hormone receptor (HR)-positive/HER2-negative locally recurrent inoperable or metastatic breast cancer—were presented at the European Society for Medical Oncology (ESMO) Congress 2022 (Abstract LBA76).
